Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Tyme Technologies Inc    TYME

TYME TECHNOLOGIES INC (TYME)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/16/2017 11/17/2017 11/20/2017 11/21/2017 11/22/2017 Date
3.72(c) 4(c) 3.99(c) 4.02(c) 4.1(c) Last
165 424 559 051 110 493 73 059 95 912 Volume
+1.92% +7.53% -0.25% +0.75% +1.99% Change
More quotes
Company
Tyme Technologies, Inc. is a clinical-stage biopharmaceutical company focused on development and commercialization of highly targeted cancer therapeutics with a broad range of oncology indications.Its lead investigational candidate, SM-88, is a novel first-in-class therapy that is designed to use... 
Sector
Biotechnology & Medical Research
Calendar
11/30 | 07:35pmPresentation
More about the company
Latest news on TYME TECHNOLOGIES INC
11/15 TYME TECHNOLOGIES : to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive..
11/14 TYME TECHNOLOGIES : Provides Clinical and Corporate Update for the Fiscal First ..
11/13 Tyme to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
11/13 TYME TECHNOLOGIES, INC. : Other Events, Financial Statements and Exhibits (form ..
11/09 TYME TECHNOLOGIES : Announces Encouraging Efficacy and Safety Data from First Hu..
11/08 Tyme Provides Clinical and Corporate Update for the Fiscal First Half 2017
11/06 TYME TECHNOLOGIES, INC. : Entry into a Material Definitive Agreement, Other Even..
11/06 TYME TECHNOLOGIES : Announces Encouraging Efficacy and Safety Data from First Hu..
11/03 Tyme to Announce Second Quarter Fiscal Year 2017 Operational Update and Sched..
11/03 TYME TECHNOLOGIES : Management's Discussion and Analysis of Financial Condition ..
More news
Sector news : Bio Therapeutic Drugs
11/22 U.S. FDA approves first two-drug HIV regimen in win for GSK
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
More sector news : Bio Therapeutic Drugs
Chart TYME TECHNOLOGIES INC
Duration : Period :
Tyme Technologies Inc Technical Analysis Chart | TYME | US90238J1034 | 4-Traders
Managers
NameTitle
Steve Hoffman Chief Executive Officer & Director
Ben Taylor President & Chief Financial Officer
Michael Demurjian Chief Operating Officer, Director & Executive VP
Guiseppe Del Priore Chief Medical Officer
Jonathan M. Eckard Chief Scientific Affairs Officer
Sector and Competitors
1st jan.Capitalization (M$)
TYME TECHNOLOGIES INC7.20%366
GILEAD SCIENCES1.69%95 098
REGENERON PHARMACEUTICALS4.73%41 637
VERTEX PHARMACEUTICALS99.59%37 187
GENMAB4.94%11 692
EXELIXIS, INC.74.72%7 731